PL3735226T3 - Kompozycje do wstrzykiwania triterpenoidowych środków przeciwgrzybiczych kapsułkowanych w liposomach - Google Patents

Kompozycje do wstrzykiwania triterpenoidowych środków przeciwgrzybiczych kapsułkowanych w liposomach

Info

Publication number
PL3735226T3
PL3735226T3 PL18834263.8T PL18834263T PL3735226T3 PL 3735226 T3 PL3735226 T3 PL 3735226T3 PL 18834263 T PL18834263 T PL 18834263T PL 3735226 T3 PL3735226 T3 PL 3735226T3
Authority
PL
Poland
Prior art keywords
liposom
triterpenoid
encapsulated
compositions
injection
Prior art date
Application number
PL18834263.8T
Other languages
English (en)
Polish (pl)
Inventor
Rajeshwar Motheram
Original Assignee
Scynexis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis, Inc. filed Critical Scynexis, Inc.
Publication of PL3735226T3 publication Critical patent/PL3735226T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
PL18834263.8T 2018-01-02 2018-12-21 Kompozycje do wstrzykiwania triterpenoidowych środków przeciwgrzybiczych kapsułkowanych w liposomach PL3735226T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862612893P 2018-01-02 2018-01-02
PCT/US2018/067216 WO2019135954A1 (en) 2018-01-02 2018-12-21 Injectable compositions of triterpenoid antifungals encapsulated in liposomes

Publications (1)

Publication Number Publication Date
PL3735226T3 true PL3735226T3 (pl) 2022-12-19

Family

ID=65024141

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18834263.8T PL3735226T3 (pl) 2018-01-02 2018-12-21 Kompozycje do wstrzykiwania triterpenoidowych środków przeciwgrzybiczych kapsułkowanych w liposomach

Country Status (27)

Country Link
US (3) US20200338002A1 (cg-RX-API-DMAC7.html)
EP (2) EP4137123A1 (cg-RX-API-DMAC7.html)
JP (3) JP7378401B2 (cg-RX-API-DMAC7.html)
KR (1) KR102694692B1 (cg-RX-API-DMAC7.html)
CN (2) CN115998684A (cg-RX-API-DMAC7.html)
AU (1) AU2018399599B2 (cg-RX-API-DMAC7.html)
CA (1) CA3087176A1 (cg-RX-API-DMAC7.html)
DK (1) DK3735226T3 (cg-RX-API-DMAC7.html)
EA (1) EA202091626A1 (cg-RX-API-DMAC7.html)
ES (1) ES2927051T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20221295T1 (cg-RX-API-DMAC7.html)
HU (1) HUE060400T2 (cg-RX-API-DMAC7.html)
IL (2) IL275758B2 (cg-RX-API-DMAC7.html)
LT (1) LT3735226T (cg-RX-API-DMAC7.html)
MA (1) MA51514A (cg-RX-API-DMAC7.html)
MD (1) MD3735226T2 (cg-RX-API-DMAC7.html)
MX (1) MX2020006992A (cg-RX-API-DMAC7.html)
PL (1) PL3735226T3 (cg-RX-API-DMAC7.html)
PT (1) PT3735226T (cg-RX-API-DMAC7.html)
RS (1) RS63687B1 (cg-RX-API-DMAC7.html)
SA (1) SA520412362B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202006313WA (cg-RX-API-DMAC7.html)
SI (1) SI3735226T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200427T1 (cg-RX-API-DMAC7.html)
TW (2) TWI857944B (cg-RX-API-DMAC7.html)
UA (1) UA126096C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019135954A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7378401B2 (ja) * 2018-01-02 2023-11-13 サイネクシス,インコーポレーテッド リポソームの中にカプセル化されたトリテルペノイド抗真菌薬の注射可能な組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
NZ589967A (en) * 2004-01-14 2012-07-27 Gilead Sciences Inc Lipid-based dispersions useful for drug delivery
ES2402659T3 (es) 2006-04-03 2013-05-07 Merck Sharp & Dohme Corp. Derivados de enfumafungina como agentes antifúngicos
CA2700530C (en) * 2007-09-28 2014-12-09 Merck Sharp & Dohme Corp. Antifungal agents
US8226965B2 (en) * 2008-04-25 2012-07-24 Nanobio Corporation Methods of treating fungal, yeast and mold infections
JP2011529038A (ja) * 2008-07-23 2011-12-01 ターゲッティド デリバリー テクノロジーズ リミテッド 真菌感染症の処置のための局所抗真菌製剤の投与方法
WO2010019204A1 (en) * 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
PE20120923A1 (es) * 2009-03-30 2012-08-27 Eisai Randd Man Co Ltd Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo
PT3247711T (pt) * 2015-01-19 2022-05-16 Scynexis Inc Novos sais e polimorfos de scy-078
JP7378401B2 (ja) * 2018-01-02 2023-11-13 サイネクシス,インコーポレーテッド リポソームの中にカプセル化されたトリテルペノイド抗真菌薬の注射可能な組成物

Also Published As

Publication number Publication date
KR20200105875A (ko) 2020-09-09
BR112020013448A2 (pt) 2020-12-01
US20230277455A1 (en) 2023-09-07
EA202091626A1 (ru) 2020-09-22
JP2025106349A (ja) 2025-07-15
AU2018399599A1 (en) 2020-07-16
UA126096C2 (uk) 2022-08-10
CA3087176A1 (en) 2019-07-11
IL275758B1 (en) 2025-03-01
SMT202200427T1 (it) 2022-11-18
JP2021508728A (ja) 2021-03-11
EP3735226A1 (en) 2020-11-11
EP3735226B1 (en) 2022-08-10
AU2018399599B2 (en) 2022-09-01
JP2024012452A (ja) 2024-01-30
TW202434242A (zh) 2024-09-01
TW201929853A (zh) 2019-08-01
DK3735226T3 (da) 2022-10-24
MA51514A (fr) 2021-04-07
KR102694692B1 (ko) 2024-08-14
CN111655237B (zh) 2023-02-03
WO2019135954A1 (en) 2019-07-11
MD3735226T2 (ro) 2023-03-31
SI3735226T1 (sl) 2022-11-30
JP7378401B2 (ja) 2023-11-13
EP4137123A1 (en) 2023-02-22
CN111655237A (zh) 2020-09-11
MX2020006992A (es) 2020-09-09
CN115998684A (zh) 2023-04-25
TWI857944B (zh) 2024-10-11
RS63687B1 (sr) 2022-11-30
IL318793A (en) 2025-04-01
PT3735226T (pt) 2022-09-20
US20250082574A1 (en) 2025-03-13
HUE060400T2 (hu) 2023-02-28
US20200338002A1 (en) 2020-10-29
LT3735226T (lt) 2022-11-10
HRP20221295T1 (hr) 2022-12-23
TWI862280B (zh) 2024-11-11
SG11202006313WA (en) 2020-07-29
NZ765771A (en) 2024-09-27
SA520412362B1 (ar) 2022-12-15
ES2927051T3 (es) 2022-11-02
IL275758B2 (en) 2025-07-01
IL275758A (en) 2020-08-31

Similar Documents

Publication Publication Date Title
DK3810201T3 (da) GIP/GLP1-agonist-sammensætninger
PL3510033T3 (pl) Związki i kompozycje jako inhibitory endosomalnych receptorów toll- podobnych
IL277778B (en) Bcl6 inhibitors
DK3350157T3 (da) Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler
EP3606559C0 (en) BIOORTHOGONAL COMPOSITIONS
DK3924443T3 (da) Compositions
EP3853332C0 (en) COMPOSITION
IL283069A (en) Methods for administering corticosteroids
EP3882323A4 (en) COMPOSITION
EP3860585A4 (en) Therapeutic compositions
IL282972A (en) Combination of small molecule cd-47 inhibitors with other anti-cancer agents
EP3849570A4 (en) Blood plasma-containing compositions
DK3840596T3 (da) Sammensætning
DK3746054T3 (da) Sammensætninger omfattende berberin
EP3590546A4 (en) COMPOSITION FOR SKIN INJECTION
EP3897152C0 (en) NEMATOCIDE COMPOSITIONS
EP3897866C0 (en) ANTIMICROBIAL COMPOSITION
EP3669854A4 (en) PHOTOPOLYMERISABLE DENTAL COMPOSITION
PT3765379T (pt) Composições
EP3829532A4 (en) KERATIN COMPOSITIONS
EP3858377A4 (en) INJECTABLE COMPOSITION
DK4076404T3 (da) Farmaceutisk pyrazolsammensætning
LT3746047T (lt) Įšvirkščiama kompozicija
EP3900790A4 (en) COMPOSITION
MX2017008893A (es) Peptidos antagonistas de prgc.